These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10804088)

  • 21. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
    Zhu Z; Bohlen P; Witte L
    Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
    Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
    Sledge GW
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome.
    Sakurada S; Kato T; Mashiba K; Mori S; Okamoto T
    Jpn J Cancer Res; 1996 Nov; 87(11):1143-52. PubMed ID: 9045943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
    Mallery SR; Morse MA; Wilson RF; Pei P; Ness GM; Bradburn JE; Renner RJ; Schuller DE; Robertson FM
    J Cell Biochem; 2003 May; 89(1):133-43. PubMed ID: 12682914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.
    Vajkoczy P; Menger MD; Vollmar B; Schilling L; Schmiedek P; Hirth KP; Ullrich A; Fong TA
    Neoplasia; 1999 Apr; 1(1):31-41. PubMed ID: 10935468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
    Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
    Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
    Zhu Z; Witte L
    Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
    Siemeister G; Martiny-Baron G; Marmé D
    Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
    [No Abstract]   [Full Text] [Related]  

  • 34. Symposium on molecular pathogenesis of respiratory diseases and its clinical implication. 4. Molecular pathogenesis of lung cancer and its molecular targeted therapy.
    Sone S; Shinohara T; Nishioka Y; Yano S
    Intern Med; 2001 Feb; 40(2):167-70. PubMed ID: 11300157
    [No Abstract]   [Full Text] [Related]  

  • 35. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells.
    Montaldo F; Maffé A; Morini M; Noonan D; Giordano S; Albini A; Prat M
    J Cell Physiol; 2000 Aug; 184(2):246-54. PubMed ID: 10867650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
    Giles FJ
    Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma.
    Skobe M; Brown LF; Tognazzi K; Ganju RK; Dezube BJ; Alitalo K; Detmar M
    J Invest Dermatol; 1999 Dec; 113(6):1047-53. PubMed ID: 10594750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo.
    Masood R; McGarvey ME; Zheng T; Cai J; Arora N; Smith DL; Sloane N; Gill PS
    Blood; 1999 Feb; 93(3):1038-44. PubMed ID: 9920854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor and Kaposi's sarcoma cells in human skin grafts.
    Samaniego F; Young D; Grimes C; Prospero V; Christofidou-Solomidou M; DeLisser HM; Prakash O; Sahin AA; Wang S
    Cell Growth Differ; 2002 Aug; 13(8):387-95. PubMed ID: 12193477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.